Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 3/2017

01-03-2017 | Original Article – Clinical Oncology

Presence of sarcomatoid differentiation as a prognostic indicator for survival in surgically treated metastatic renal cell carcinoma

Authors: Liangyou Gu, Hongzhao Li, Hanfeng Wang, Xin Ma, Lei Wang, Luyao Chen, Wenlei Zhao, Yu Zhang, Xu Zhang

Published in: Journal of Cancer Research and Clinical Oncology | Issue 3/2017

Login to get access

Abstract

Purpose

To assess the prognostic significance of sarcomatoid differentiation for surgically treated metastatic renal cell carcinoma (mRCC).

Methods

Patients undergoing cytoreductive nephrectomy for mRCC in our center between 2006 and 2014 were included. All enrolled patients were separated into two groups according to the presence of sarcomatoid differentiation. Clinical and pathological variables were recorded. Student’s t test or Chi-square test was applied to compare them. Univariate and multivariate Cox regression were performed to determine independent prognostic factors for oncologic outcomes.

Results

Of the 184 patients with mRCC included, 27 (14.7%) patients presented with sarcomatoid differentiation. The presence of sarcomatoid differentiation was associated with higher rates of non-clear cell histology (P = 0.009), higher Fuhrman grade (P < 0.001), higher rates of presenting tumor necrosis (P = 0.005), worse IMDC risk group (P = 0.022), and MSKCC risk group (P = 0.020). Patients with sarcomatoid differentiation showed shorter median progression-free survival and overall survival. Multivariate analysis identified that sarcomatoid differentiation was independently associated with progression-free survival (hazard ratio [HR]: 2.002, 95% CI 1.047–3.828; P = 0.036) and overall survival (HR: 1.922, 95% CI 1.073–3.445; P = 0.028). Sarcomatoid differentiation remained to be independently associated with inferior PFS (HR: 2.097, 95% CI 1.091–4.030; P = 0.026) and OS (HR: 2.245, 95% CI 1.276–3.951; P = 0.005) for clear cell mRCC.

Conclusion

The presence of sarcomatoid differentiation is independently associated with poor oncologic outcomes for surgically treated mRCC patients. The association remains significant when the subject of study is restricted to clear cell mRCC.
Literature
go back to reference Cheville JC, Lohse CM, Zincke H, Weaver AL, Leibovich BC, Frank I, Blute ML (2004) Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol 28:435–441CrossRefPubMed Cheville JC, Lohse CM, Zincke H, Weaver AL, Leibovich BC, Frank I, Blute ML (2004) Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol 28:435–441CrossRefPubMed
go back to reference de Peralta-Venturina M et al (2001) Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol 25:275–284CrossRefPubMed de Peralta-Venturina M et al (2001) Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol 25:275–284CrossRefPubMed
go back to reference Farrow GM, Harrison EG Jr, Utz DC (1968) Sarcomas and sarcomatoid and mixed malignant tumors of the kidney in adults. 3. Cancer 22:556–563CrossRefPubMed Farrow GM, Harrison EG Jr, Utz DC (1968) Sarcomas and sarcomatoid and mixed malignant tumors of the kidney in adults. 3. Cancer 22:556–563CrossRefPubMed
go back to reference Haas NB et al (2012) A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol (Northwood, London, England) 29:761–767. doi:10.1007/s12032-011-9829-8 CrossRef Haas NB et al (2012) A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol (Northwood, London, England) 29:761–767. doi:10.​1007/​s12032-011-9829-8 CrossRef
go back to reference Kanamaru H, Sasaki M, Miwa Y, Akino H, Okada K (1999) Prognostic value of sarcomatoid histology and volume-weighted mean nuclear volume in renal cell carcinoma. BJU Int 83:222–226CrossRefPubMed Kanamaru H, Sasaki M, Miwa Y, Akino H, Okada K (1999) Prognostic value of sarcomatoid histology and volume-weighted mean nuclear volume in renal cell carcinoma. BJU Int 83:222–226CrossRefPubMed
go back to reference Kwak C, Park YH, Jeong CW, Jeong H, Lee SE, Moon KC, Ku JH (2007) Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma. J Surg Oncol 95:317–323. doi:10.1002/jso.20669 CrossRefPubMed Kwak C, Park YH, Jeong CW, Jeong H, Lee SE, Moon KC, Ku JH (2007) Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma. J Surg Oncol 95:317–323. doi:10.​1002/​jso.​20669 CrossRefPubMed
go back to reference Merrill MM et al (2015) Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: natural history and outcomes after surgical resection with curative intent. Urol Oncol. doi:10.1016/j.urolonc.2014.11.021 Merrill MM et al (2015) Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: natural history and outcomes after surgical resection with curative intent. Urol Oncol. doi:10.​1016/​j.​urolonc.​2014.​11.​021
go back to reference Mian BM, Bhadkamkar N, Slaton JW, Pisters PW, Daliani D, Swanson DA, Pisters LL (2002) Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol 167:65–70CrossRefPubMed Mian BM, Bhadkamkar N, Slaton JW, Pisters PW, Daliani D, Swanson DA, Pisters LL (2002) Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol 167:65–70CrossRefPubMed
Metadata
Title
Presence of sarcomatoid differentiation as a prognostic indicator for survival in surgically treated metastatic renal cell carcinoma
Authors
Liangyou Gu
Hongzhao Li
Hanfeng Wang
Xin Ma
Lei Wang
Luyao Chen
Wenlei Zhao
Yu Zhang
Xu Zhang
Publication date
01-03-2017
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 3/2017
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-016-2304-3

Other articles of this Issue 3/2017

Journal of Cancer Research and Clinical Oncology 3/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.